Clinical trial
An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)
NCT03338621 is registered in ClinicalTrials.gov with Global Alliance for TB Drug Development as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)
- Lead sponsor
- Global Alliance for TB Drug Development
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- July 30, 2018
- Completion date
- June 10, 2022
- Enrollment
- 455 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
drug-resistant tuberculosis, tuberculosis, tuberculosis, mdr, tuberculosis, multidrug-resistant, tuberculosis, pulmonary